BioCardia, Inc. has announced a significant milestone in its journey towards regulatory approval for its CardiAMP Cell Therapy System. On November 6, 2026, the company revealed that it has completed the clinical consultation process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This step is crucial as it brings BioCardia closer to submitting a marketing approval application in Japan, a leading market for cardiovascular therapies.

BioCardia, Inc. is a company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). BioCardia is publicly traded on the Nasdaq under the ticker symbol BCDA.

According to the filing, BioCardia stated, "With the completion of consultations with PMDA regarding our application materials, we are closer to the day when we can provide CardiAMP cell therapy to heart failure patients in Japan." This statement underscores the company's commitment to addressing the significant unmet medical needs of patients suffering from ischemic heart failure.

The completion of this consultation process is expected to impact various stakeholders, including patients in Japan who are in need of innovative therapies for heart failure. The CardiAMP Cell Therapy System aims to offer a minimally invasive, catheter-based autologous cell therapy option, which could be a game-changer for this patient population.

Looking ahead, the filing does not specify the next steps following this consultation. However, the completion of this process positions BioCardia to initiate the final regulatory approval review, with the company targeting the treatment of its first patients in Japan and the realization of commercial revenues by 2028.